GB876027A - New vaccines and a process for their manufacture - Google Patents

New vaccines and a process for their manufacture

Info

Publication number
GB876027A
GB876027A GB8863/58A GB886358A GB876027A GB 876027 A GB876027 A GB 876027A GB 8863/58 A GB8863/58 A GB 8863/58A GB 886358 A GB886358 A GB 886358A GB 876027 A GB876027 A GB 876027A
Authority
GB
United Kingdom
Prior art keywords
virus
vaccines
metal oxide
antigen
bacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB8863/58A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of GB876027A publication Critical patent/GB876027A/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
GB8863/58A 1957-03-19 1958-03-19 New vaccines and a process for their manufacture Expired GB876027A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DED25189A DE1041647B (de) 1957-03-19 1957-03-19 Verfahren zur Herstellung von im Adsorptionsgleichgewicht stehenden Depotimpfstoffen

Publications (1)

Publication Number Publication Date
GB876027A true GB876027A (en) 1961-08-30

Family

ID=7038445

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8863/58A Expired GB876027A (en) 1957-03-19 1958-03-19 New vaccines and a process for their manufacture

Country Status (4)

Country Link
BE (1) BE565793A (enExample)
DE (1) DE1041647B (enExample)
GB (1) GB876027A (enExample)
SE (1) SE314164B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3470067A (en) * 1967-09-19 1969-09-30 Pfizer & Co C Concentration and purification of viruses from particulate magnetic iron oxide-virus complexes
FR2854803A1 (fr) * 2003-05-16 2004-11-19 Aventis Pasteur Composition vaccinale comprenant du phosphate de fer a titre d'adjuvent vaccinal.
EP1361859A4 (en) * 2001-02-15 2009-05-20 Kos Life Sciences Inc PARTICLES WITH MODULATED RELEASE FOR AEROSOL LEAVES

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19511276C2 (de) * 1995-03-27 1999-02-18 Immuno Ag Adjuvans auf der Basis kolloidaler Eisenverbindungen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE885466C (de) * 1951-09-22 1953-08-06 Byk Gulden Lomberg Chem Fab Verfahren zur Herstellung eines Impfstoffes gegen Schlafkrankheit

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3470067A (en) * 1967-09-19 1969-09-30 Pfizer & Co C Concentration and purification of viruses from particulate magnetic iron oxide-virus complexes
EP1361859A4 (en) * 2001-02-15 2009-05-20 Kos Life Sciences Inc PARTICLES WITH MODULATED RELEASE FOR AEROSOL LEAVES
FR2854803A1 (fr) * 2003-05-16 2004-11-19 Aventis Pasteur Composition vaccinale comprenant du phosphate de fer a titre d'adjuvent vaccinal.
WO2004103408A3 (fr) * 2003-05-16 2005-03-17 Aventis Pasteur Composition vaccinale comprenant du phosphate de fer a titre d’adjuvant vaccinal
JP2006528958A (ja) * 2003-05-16 2006-12-28 サノフィ・パスツール ワクチンのアジュバントとしてリン酸鉄を含むワクチン組成物

Also Published As

Publication number Publication date
DE1041647B (de) 1958-10-23
SE314164B (enExample) 1969-09-01
BE565793A (enExample) 1900-01-01

Similar Documents

Publication Publication Date Title
van Roosmalen et al. Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria
Coursaget et al. Simultaneous administration of diphtheria-tetanus-pertussis-polio and hepatitis B vaccines in a simplified immunization program: immune response to diphtheria toxoid, tetanus toxoid, pertussis, and hepatitis B surface antigen
Chandran et al. Development of a recombinant epsilon toxoid vaccine against enterotoxemia and its use as a combination vaccine with live attenuated sheep pox virus against enterotoxemia and sheep pox
JPH01230532A (ja) 新規なワクチン及びその製法
Vershilova The use of live vaccine for vaccination of human beings against brucellosis in the USSR
Tapa et al. Controlled field trial on the effectiveness of one and two doses of acetone-inactivated and dried typhoid vaccine
Cate et al. Clinical trials of monovalent influenza A/New Jersey/76 virus vaccines in adults: reactogenicity, antibody response, and antibody persistence
CN107802831A (zh) 一种灭活乳酸菌疫苗佐剂
Spradbrow et al. Recent isolates of Newcastle disease virus in Australia
GB1256456A (en) Ethylethyleneimine as inactivating agent in antigen-containing pharmaceutical preparations
CN1217212A (zh) 甲肝-麻疹二联疫苗及其生产方法
US3155589A (en) Parenteral extravascular injectable vaccines for simultaneous immunization of canidae against rabies, canine distemper, and infectious canine hepatitis
Schwarz et al. Modification of infectious bovine rhinotracheitis (IBR) virus in tissue culture and development of a vaccine
CN103656660B (zh) 一种动物活疫苗耐热冻干保护剂、其制备方法及应用
GB1461188A (en) Live influenza virus vaccines and preparation thereof
GB1256457A (en) Diethylaminoethyldextran (deae-d) as adjuvant for vaccines for active immunisation
Eidson et al. Vaccination of broiler chicks from breeder flocks immunized with a live or inactivated oil emulsion Newcastle disease vaccine
Saito et al. Attenuation of the myxoma virus and use of the living attenuated virus as an immunizing agent for myxomatosis
Weiss Observations on Bacterium melaninogenicum: Demonstration of Fibrinolysin, Pathogenicity and Serological Types.
Stashak et al. The serum antibody response to bacteriophage ΦX174 in germ-free and conventionally reared mice: I. Assay of neutralizing antibody by a 50 per cent neutralization method
US3318775A (en) Production of viral antigens with n-acetyl-ethyleneimine
Stalheim Viable, avirulent Leptospira interrogans serotype pomona vaccine: Preservation in liquid nitrogen
Rappaport et al. Development of a purified cholera toxoid. III. Refinements in purification of toxin and methods for the determination of residual somatic antigen
CN108175854B (zh) 一种乙脑疫苗的冻干制剂
Smith The basis of immunity to anthrax